| P50 | author | Kuen-Feng Chen | Q39577938 |
| P2093 | author name string | Chung-Wai Shiau | |
| | Man-Hsin Hung | |
| | Wei-Tien Tai | |
| P2860 | cites work | Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway | Q24305237 |
| | Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis | Q24632905 |
| | STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation | Q24644334 |
| | SOCS, inflammation, and cancer | Q26991808 |
| | Crystal structure of human protein-tyrosine phosphatase SHP-1 | Q27640158 |
| | Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation | Q27667430 |
| | Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1 | Q27765696 |
| | Management of hepatocellular carcinoma: An update | Q27860530 |
| | Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 |
| | Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins | Q27860890 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production | Q29614596 |
| | Hepatocellular carcinoma | Q29615765 |
| | Hepatocellular carcinoma | Q29616359 |
| | STATs in oncogenesis | Q29617571 |
| | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 |
| | BAY 43-9006: preclinical data | Q30736965 |
| | Role of STAT3 in cancer metastasis and translational advances | Q31142794 |
| | Antitumor activity of sorafenib in FLT3-driven leukemic cells | Q33268279 |
| | Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 |
| | Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation | Q33737707 |
| | STAT family of transcription factors in cytokine-mediated biological responses | Q33922381 |
| | Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors | Q33941380 |
| | Stat3 dimerization regulated by reversible acetylation of a single lysine residue | Q34384817 |
| | Regulation of STAT-dependent pathways by growth factors and cytokines. | Q34413932 |
| | Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity | Q34555453 |
| | Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention | Q34595904 |
| | c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. | Q35021436 |
| | In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression | Q35074604 |
| | The function of the protein tyrosine phosphatase SHP-1 in cancer | Q35092309 |
| | Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis | Q35167959 |
| | Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. | Q35626914 |
| | Turning off signal transducer and activator of transcription (STAT): the negative regulation of STAT signaling | Q35882293 |
| | Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3 | Q36446884 |
| | Multiple interactive factors in hepatocarcinogenesis | Q38174386 |
| | Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design | Q38192888 |
| | Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. | Q39116687 |
| | Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling. | Q39496493 |
| | Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma | Q39585554 |
| | Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. | Q39649432 |
| | Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. | Q39726725 |
| | Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. | Q40192837 |
| | Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma | Q40258085 |
| | Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells | Q40602668 |
| | Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling | Q40837817 |
| | Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells | Q40972355 |
| | The JAK-STAT pathway: summary of initial studies and recent advances. | Q41029001 |
| | Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein | Q41326706 |
| | ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. | Q42443548 |
| | Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. | Q42833476 |
| | Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma | Q44189596 |
| | First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study | Q44599939 |
| | Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice | Q45363162 |
| | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 |
| P433 | issue | 41 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 15269-15274 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy | |
| P478 | volume | 20 | |